Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma
OBJECTIVES: I. Assess the efficacy and toxicity of nitrocamptothecin in patients with
metastatic melanoma.
OUTLINE: Patients are stratified according to disease (choroidal vs nonchoroidal). Patients
receive oral nitrocamptothecin daily on days 1-5. Treatment continues weekly for at least 8
weeks (2 courses) in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 28-74 patients (14-37 per stratum) will be accrued for this
study.
Interventional
Primary Purpose: Treatment
Show-Li Sun, MD
Study Chair
Astex Pharmaceuticals
United States: Federal Government
CDR0000067911
NCT00005875
January 1999
Name | Location |
---|---|
SuperGen, Incorporated | Dublin, California 94568 |